Mollie Wood, PhD, MPH is an assistant professor in Epidemiology at UNC Gillings School of Global Public Health. Her research focuses on the safety of medication use during pregnancy, specifically for chronic conditions like depression, migraine, and diabetes, combining expertise in reproductive epidemiology, pharmacoepidemiology, and methods.

Sonia Grandi, PhD is a Scientist and Assistant Professor at the Research Institute of the Hospital for Sick Children and University of Toronto. As a perinatal pharmacoepidemiologist, her research focuses on the safety of treatments for chronic cardiometabolic and immune-mediated conditions in pregnancy. She also specializes in causal inference methods using administrative health data.

Stephan Lanes, PhD, MPH is a Principal Scientist at Carelon Research, part of Elevance Health. He focuses on drug safety and the application of epidemiologic methods to health data in collaboration with industry, academic, and government partners

Trish Melton, PhD is Managing Director of Mime Solutions Ltd and a recognized leader in pharmaceutical engineering with over 25 years of ISPE membership and service. She is the recipient of the 2025 ISPE Richard B. Purdy Distinguished Achievement Award, in recognition of her long-term contributions to the industry. Dr. Melton has been deeply involved in ISPE's Guidance Documents Committee, serving as Chair from 2021 to 2024, and has contributed to the development of more than 80 ISPE Guidance Documents. Her work spans project management, sustainability, and pharmaceutical supply chain best practices, making her a leading voice on the structural and operational challenges facing the industry today.

Joseph Mitchell is an affiliated researcher at the Karolinska Institutet (KI), where his research focuses on the utility of pharmacovigilance in antibiotic resistance surveillance. He also works in pharmacovigilance and safety signal management. He is currently employed at ALK-Abelló. His broader research interests include One Health, ecopharmacovigilance, and causality assessment , areas that sit at the intersection of environmental change, drug safety, and public health, and are directly relevant to the challenges of climate-related drug shortages.

Robbie M. Parks PhD's research focuses on the intersections of climate change, public health, and equity, using quantitative methods to understand and address health impacts. He is a tenure-track Assistant Professor of Environmental Health Sciences at Columbia University's Mailman School of Public Health and an NIH NIEHS K99/R00 Fellow, with funding from NIH, the Wellcome Trust, NSF, and other sources; several of his lab's publications have been recognized as NIEHS papers of the year and month. He teaches multiple graduate courses at Columbia, leads advanced training programs in Bayesian modeling and climate-health attribution, and mentors trainees across all academic levels. His academic training includes a postdoctoral fellowship at Columbia's Earth Institute/Climate School, a PhD from Imperial College London, and a BA/MA in Physics from the University of Oxford. His work has been featured in major media outlets including The New Yorker, The New York Times, and National Geographic. He is a first-generation academic of Filipino heritage and a fellow of both the Agents of Change in Environmental Justice program and the National Academy of Sciences Frontiers of Science.

Soko Setoguchi, MD, DrPH is a cardiologist by training, board-certified internist, and epidemiologist, a Professor of Medicine, Director of Clinical Research Education, Director of Clinician Researcher Track, Medicine Residency Program, Department of Medicine, Rutgers Robert Wood Johnson Medical School (RWJMS) and Professor of Epidemiology at Rutgers School of Public Health. She is also Co-Director of the Master of Science in Clinical and Translational Science (MS-CTS) at Rutgers School of Graduate Studies. Dr. Setoguchi is recognized as an international leader in the field of pharmacoepidemiology and comparative effectiveness research studying the health effects of medications, medical devices, and other medical products in populations. She has authored more than 130 peer-reviewed papers in leading medical journals and has been funded by both federal and non-federal sources for her pharmacoepidemiology research program. Her research uses real world data to perform health services and outcomes research and comparative effectiveness research for medications and implantable medical devices in patients with chronic disease.

Jerry Avorn, MD, FISPE, is a professor of medicine at Harvard Medical School and a senior internist in the Mass General Brigham health-care system. His group was among the first to use medication and clinical outcome claims data to study patterns of prescribing, adherence, outcomes, and adverse events. A past president of ISPE and a Fellow of the Society, he built a leading research center at Harvard to study medication use, outcomes, costs, and policies – the Division of Pharmacoepidemiology and Pharmacoeconomics (DoPE) of the Department of Medicine at the Brigham and Women's Hospital. He also developed the educational outreach approach known as "academic detailing," providing non-commercial evidence-based information about medications to prescribers. One of the nation's most highly cited researchers, Dr. Avorn has written or cowritten over 600 papers in the medical literature as well as commentaries in JAMA, The New England Journal of Medicine, The New York Times, and The Washington Post. He is the author of Rethinking Medications: Truth, Power, and the Drugs You Take (Simon & Schuster, 2025 – www.RethinkMeds.info ).